As deadly ‘superbugs’ outsmart antibiotics, a Penn scientist uses artificial intelligence to design new ones

The Philadelphia Inquirer-November 2, 2019. Big drug companies steer clear of developing new antibiotics largely because the drugs are not moneymakers, said Eili Klein, a senior fellow at the Center for Disease Dynamics, Economics & Policy, a think tank with offices in Washington and New Delhi. By nature, the drugs are designed to be used for the short term, some of them only as a last resort.